B O O K - American College of Rheumatology

More documents

Recommendations

Info

INVITED SPEAKER /MODERATOR INDEX P Paget, Stephen A, MD Giant Cell Arteritis - Diagnosis and Therapy . . . . . . . . . . . . . . . . . . 69 Disclosure: Nothing to Disclose REF Marshall J. Schiff, MD, Memorial Lectureship: Everything a Rheumatologist Should Know About Spine Surgery but Was Afraid to Ask . . . . . . . . . . . . . . . . . . 84 Disclosure: Nothing to Disclose Paiva, Eduardo S, MD When Pieces Don’t Fit . . . . . . . . . . . .120 Disclosure: Apsen Brazil, 5; Eli Lilly Brazil, 8; Pfizer Brazil, 8 Passo, Murray H, MD Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis . . . . . . . . . . . . . . . . . . . . 29 Disclosure: Pfizer, 2, 5 Pennington, Scott D, MD Total Shoulder Arthroplasty and Reverse Total Shoulder Arthroplasty: Surgery and Rehabilitation. . . . . . . . . . . . . . .147 Disclosure: Nothing to Disclose Perez-Masuelli, Carmen, MD The Ideal Rheumatology Practice . . . . . .104 Disclosure: Nothing to Disclose Perlman, Harris R, PhD Innate Immunity and Inflammation . . . . . 30 Disclosure: Nothing to Disclose Phillips, Kristine, MD, PhD Disparities and Pain: Examining Research, Practice and Policy . . . . . . . . . . . . . . 95 Disclosure: Nothing to Disclose Interstitial Lung Diseases in the Rheumatic Diseases . . . . . . . . . . . . . . . . . . . .109 Disclosure: Nothing to Disclose Pierangeli, Silvia S, PhD Antiphospholipid Syndrome . . . . . . . . . 87 Disclosure: Nothing to Disclose Pillai, Shiv, MD, PhD Session I: B cell Development . . . . . . . . 20 Disclosure: Nothing to Disclose Pincus, Theodore, MD WK - Patient Questionnaires to Monitor Status and Document Improvement in Standard Care: Practical Considerations . . . . . . . . . . .102 Disclosure: Nothing to Disclose Clinical Research Methodology . . . . . . .107 Disclosure: Nothing to Disclose Pisetsky, David S, MD, PhD From Fat to Joints - The Vicious Side of Adipokines . . . . . . . . . . . . . . . . . . . 98 Disclosure: Nothing to Disclose Plaas, Anna H, PhD Molecular Mechanisms of Inflammatory Signaling in Cartilage Destruction . . . . . . 27 Disclosure: Pfizer, 2; Smith Nephew, 2 Osteoarthritis . . . . . . . . . . . . . . . . .110 Disclosure: Pfizer Inc, 2; Smith Nephew, 2 Plass, Nicole D, BSN, MPA The Multidisciplinary Approach to Hereditary Periodic Fever Syndromes . . . . . . . . . . 58 Disclosure: Nothing to Disclose Pollock, P. Scott MD Musculoskeletal Ultrasound Course for Rheumatologists - Day One. . . . . . . . . . 17 Disclosure: TBA Musculoskeletal Ultrasound Course for Rheumatologists - Day Two. . . . . . . . . . 22 Disclosure: TBA Poole, Janet L, PhD, OTR Adaptations and Solutions to Help People with Scleroderma Continue to Work . . . . . . .102 Disclosure: American College of Rheumatology Research Education Foundation, 2 Measure by Measure: Assessing Psychological Health and Well-Being in Scleroderma . . .135 Disclosure: American College of Rheumatology Research Education Foundation, 2 Practice Potpourri . . . . . . . . . . . . . . . 86 Disclosure: American College of Rheumatology Research Education Foundation, 2 ARHP General Session I - Keynote Address. . . . . . . . . . . . . . . . . . . . . 32 Disclosure: American College of Rheumatology Research Education Foundation, 2 ARHP General Session II: ARHP Distinguished Lecturer . . . . . . . . . . . . . . . . . . . . 62 Disclosure: American College of Rheumatology Research Education Foundation, 2 Moderators Orientation . . . . . . . . . . . 27 Disclosure: American College of Rheumatology Research Education Foundation, 2 Pope, Janet E, MD, MPH Raynaud’s and Digital Ischemia . . . . 65, 105 Disclosure: Actelion, 2, 5; Mediquest, 5; Pfizer, 5; UT, 2 Pope, Richard M, MD Toll-like Receptors and Inflammation: Towards Innovative Treatment of Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . 38 Disclosure: Nothing to Disclose Porter, Duncan, MD Rheumatoid Arthritis Treatment 2010: Traditional DMARDs, Biologic DMARDs and Newer Treatment Strategies . . . . . . . . 114 Disclosure: Abbott, 5, 8; Pfizer, 2; Roche, 2, 5; Schering Plough, 5, 8; UCB, 5; Wyeth, 2 Pruijn, Ger, PhD The Biology of Citrullination . . . . . . . . . 68 Disclosure: Nothing to Disclose R Radbruch, Andreas H, PhD Session II: B cell Activation and Trafficking . . . . . . . . . . . . . . . . . . . 20 Disclosure: Nothing to Disclose Radstake, Timothy RDJ, MD, PhD Toll-like Receptors and Inflammation: Towards Innovative Treatment of Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . 38 Disclosure: Nothing to Disclose Scleroderma-Biomarkers . . . . . . . . . . 111 Disclosure: Nothing to Disclose Randall, Troy, PhD Session III: B cells in the Immune Response. 23 Disclosure: Vaccinex, 2 Rapoff, Michael A, PhD Daltroy Memorial Lecture: Adherence to Medical Regimens for Rheumatic Diseases and the Importance of Patient-Clinician Communication . . . . . . . . . . . . . . . . 61 Disclosure: Nothing to Disclose ARHP Networking at Noon . . . . . . . . . . 63 Disclosure: Nothing to Disclose Rawlings, David J, MD Session II: B cell Activation and Trafficking . 20 Disclosure: Nothing to Disclose Ray, Laura E, MA, MLS Web-based Support of Clinical Practice and Teaching: Twittering, Blogging, and Doing the Wiki. . . . . . . . . . . . . . . . . . . . . . .120 Disclosure: Nothing to Disclose ARHP Networking at Noon . . . . . . . . . . 64 Disclosure: Nothing to Disclose Raza, Karim, BA, PhD The Preclinical Stage of Rheumatoid Arthritis: Towards Prevention of Disease? . . . . . . . 76 Disclosure: Cellzome, 2; UCB, 2, 5; Wyeth, 2 Reed, Ann M, MD Juvenile Dermatomyositis in 2010 - From Bench to Bedside . . . . . . . . . . . . . . . . . . . 31 Disclosure: Nothing to Disclose Reiff, Andreas O, MD Inflammatory Eye Disease . . . . . . . . . . 35 Disclosure: AMGEN, PFIZER, ABBOTT, MERCK, 8 Integrating Immunology and Biologics into Clinical Practice . . . . . . . . . . . . . . . . 26 Disclosure: AMGEN, PFIZER, ABBOTT, MERCK, 8 Richardson, Bruce C, MD, PhD The Revolution of Epigenetics in Autoimmunity . . . . . . . . . . . . . . . . . 47 Disclosure: Nothing to Disclose Rider, Lisa G, MD Practice Potpourri . . . . . . . . . . . . . . . 86 Disclosure: Nothing to Disclose Myositis . . . . . . . . . . . . . . . . . . . .110 Disclosure: Nothing to Disclose Ridley, David J, MD The Ideal Rheumatology Practice . . . . . .104 Disclosure: BMS, 2; Celgene, 2; Centacor, 2; Genentech, 2; UCB, 2 Rigby, William F. C, MD ACR REF Within Our Reach: Finding a Cure for Rheumatoid Arthritis . . . . . . . . . . . . . 45 Disclosure: Nothing to Disclose Riskind, Peter, MD, PhD Update on Multiple Sclerosis. . . . . . . . . 59 Disclosure: Biogen idec, 5; Teva, 5, 9 Rock, Kenneth L, MD Cell Death: Receptors, Sensors and Inflammatory Pathways. . . . . . . . . . . .114 Disclosure: Sanofi-Aventis, 2 Roediger, Joan M, JD, LLM Contract Negotiations for Physicians . . . . 65 Disclosure: Nothing to Disclose 310 2010 Program Book
Rogers, Joan C, PhD, OTR/ L Understanding Functional Activity in Rheumatoid Arthritis: What We Know and What We Don’t Know . . . . . . . . . . . . . . . . 86 Disclosure: Nothing to Disclose Rose, Carlos D, MD Pediatric Spondylarthropathies: From Genetics to the Clinic . . . . . . . . . . . . . . . . . .136 Disclosure: Nothing to Disclose ILAR Global Health Project . . . . . . . . . . 84 Disclosure: Nothing to Disclose Rosenbaum, James T, MD Molecular Mechanisms of Ocular Inflammation . . . . . . . . . . . . . . . . .121 Disclosure: Nothing to Disclose Rosenzweig, Holly L, PhD Molecular Mechanisms of Ocular Inflammation . . . . . . . . . . . . . . . . .121 Disclosure: Nothing to Disclose Roth, Johannes, MD Musculoskeletal Ultrasound Course for Rheumatologists - Day One. . . . . . . . . . 18 Disclosure: Nothing to Disclose Musculoskeletal Ultrasound Course for Rheumatologists - Day Two. . . . 22Disclosure: Nothing to Disclose Imaging. . . . . . . . . . . . . . . . . . . . .108 Disclosure: Nothing to Disclose Roth-Wojcicki, Elizabeth L, RN MS CPNP Integrating Immunology and Biologics into Clinical Practice . . . . . . . . . . . . . . . . 25 Disclosure: Nothing to Disclose Roubey, Robert A. S, MD Antiphospholipid Syndrome . . . . . . . . . 56 Disclosure: Quest Diagnostics, 5 Ruderman, Eric M, MD The Great Debate: Is it Time to Use Biologics as First-line Therapy in Rheumatoid Arthritis? . 39 Disclosure: Nothing to Disclose Update on Safety Issues in the Treatment of Rheumatic Diseases – From the Food and Drug Administration and Beyond . . . . . . . . . 77 Disclosure: Nothing to Disclose Methotrexate 2010 . . . . . . . . . . . . . . 55 Disclosure: Nothing to Disclose Ruffing, Victoria L, RN Patient Education on the Run . . . . . . . . 95 Disclosure: Nothing to Disclose Rye, Kerry-Anne, PhD A Critical Role for Lipid Metabolism in the Interplay between Atherosclerosis and Autoimmune Disorders . . . . . . . . . . . .121 Disclosure: Nothing to Disclose S Saag, Kenneth G, MD, MSc Welcome and Introductions . . . . . . . . . 19 Disclosure: Amgen, 5, 8; AstraZenica, 5; Eli Lilly, 5; Genentech, 5; GlaxoSmithKline, 5; Merck, 5; NicOx, 5; Nitec, 5; Novartis, 5, 8; Pfizer, 5; Proctor & Gamble, 5; Takeda, 5; UCB, 5 Curbside Consults - Ask the Professors . . . 62 Disclosure: Amgen, 5, 8; AstraZenica, 5; Eli Lilly, 5; Genentech, 5; GlaxoSmithKline, 5; Merck, 5; NicOx, 5; Nitec, 5; Novartis, 5, 8; Pfizer, 5 Proctor & Gamble, 5; Takeda, 5; UCB, 5 Salmon, Jane E, MD Antiphospholipid Syndrome . . . . . . . . . 87 Disclosure: Nothing to Disclose Salt, Elizabeth G, PhD, ARNP Juvenile Fibromyalgia . . . . . . . . . . . . . 53 Disclosure: Nothing to Disclose Samuels, Jonathan, MD Musculoskeletal Ultrasound Course for Rheumatologists - Day One. . . . . . . . . . 18 Disclosure: Nothing to Disclose Musculoskeletal Ultrasound Course for Rheumatologists - Day Two. . . . . . . . . . 22 Disclosure: Nothing to Disclose Sanchez-Guerrero, F. Jorge, MD The Brain and Systemic Lupus Erythematosus: 2010 Update (Clinical Review) . . . . . . . . 66 Disclosure: Nothing to Disclose Systemic Lupus Erythematosus: Central Nervous System . . . . . . . . . . . . . . . . . . 52, 106 Disclosure: Nothing to Disclose Sandborg, Christy I, MD The Changing Face of the Rheumatology Workforce: Gender Issues in the Workplace . . . . . . . . . . . . . . . . . . . . . . . . . 94 Disclosure: Nothing to Disclose Sanz, Inaki, MD Session III: B cells in the Immune Response. . . . . . . . . . . . . . . . . . . . 23 Disclosure: Biogen, 2; GSK, 2, 5 Scalapino, Kenneth J, MD Iatrogenic Misadventures: Complex Cases . 85 Disclosure: Nothing to Disclose Scanzello, Carla R, MD, PhD Osteoarthritis . . . . . . . . . . . . . . . . .110 Disclosure: Amgen, 9 Schlenk, Elizabeth A, PhD, RN What’s New and Noteworthy in 2010: A Review of Rheumatology Research for Health Professionals. . . . . . . . . . . . . . . . . . 76 Disclosure: Nothing to Disclose ARHP Networking at Noon . . . . . . . . . . 64 Disclosure: Nothing to Disclose Schlesinger, Naomi, MD Crystallizing Your Assessment and Treatment of Difficult to Treat Gout . . . . . . . . . . . . .114 Disclosure: Novartis, 2, 5;Takeda, 8; URL Pharma, 9 Schmidt, Wolfgang A, MD Musculoskeletal Ultrasound Course for Rheumatologists-Day One . . . . . . . . . . 18 Disclosure: Abbott, 2; Abbott, 8; Actelion, 2, 8; Berlin Chemie, 8; BMS, 2, 8; Chugai, 2, 8; Esaote, 2, 8; Essex, 2, 8; GE, 2; Lilly, 2; Medac, 2, 8; Merck, 8; MSD, 2, 8; Novartis, 2, 8; Pfizer, 2, 8; Roche, 2, 8; Schering - Plough, 2, 8; UCB, 2; Wyeth, 2, 8 Musculoskeletal Ultrasound Course for Rheumatologists - Day Two. . . . . . . . . . 22 Disclosure: Abbott, 2, 8; Actelion, 2, 8; Berlin Chemie, 8; BMS, 2, 8; Chugai, 2, 8; Esaote, 2, 8; Essex, 2, 8; GE, 2; Lilly, 2; Medac, 2, 8; Merck, 8; MSD, 2, 8; Novartis, 2, 8; Pfizer, 2, 8; Roche, 2, 8; Schering - Plough, 2, 8; UCB, 2; Wyeth, 2, 8 Schneider, Rayfel, MBBCh Still’s Disease, Febrile Illnesses . . . . . . . . 83 Disclosure: Hoffman-La Roche, 5 Schnitzer, Thomas J, MD, PhD Osteoarthritis - What is New in Old Joints .122 Disclosure: AstraZeneca, 9; Eli Lilly & Co., 5; Logical Therapeutics, 5; NicOx, 1, 5; Nordic Bioscience, 2; Pfizer, 2 Seo, Philip, MD Treatment of Wegener’s Granulomatosis/ Microscopic Polyangiitis: Understanding and Applying the Data from Recent Clinical Trials . . . . . . . . . . . . . . . . . . . . . . . . . . . 48 Disclosure: Nothing to Disclose Serre, Guy B, MD, PhD The Biology of Citrullination . . . . . . . . . 68 Disclosure: bioMérieux (FRANCE), 7 Shadick, Nancy A, MD, MPH Rheumatoid Arthritis: Difficult Cases . . . .130 Disclosure: AMGEN, 2; Biogen Idec, 2; Crescendo Biosciences, 2 Rheumatoid Arthritis: Difficult Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . 29 Disclosure: AMGEN, 2; Biogen Idec, 2; Crescendo Biosciences, 2 Shakoor, Najia, MD Osteoarthritis - What is New in Old Joints .122 Disclosure: Nothing to Disclose Shen, Nan, MD B cell Effectors and Regulators . . . . . . . 113 Disclosure: Nothing to Disclose Tolerogenic Dendritic Cells: Regulators of Immune Reactivity and Therapeutic Agents in Autoimmune Disease . . . . . . . . . . . . 101 Disclosure: Nothing to Disclose Sherry, David D, MD Career Opportunities in Rheumatology: Making a Choice . . . . . . . . . . . . . . . . . . . .112 Disclosure: Nothing to Disclose Shulman, Neil, MD ARHP General Session I - Keynote Address . 32 Disclosure: Nothing to Disclose Silver, Richard M, MD Systemic Sclerosis: New Therapeutic Approaches . . . . . . . . . . . . . . . . . .122 Disclosure: Boehringer Ingelheim, 2 Silverman, Gregg J, MD Session V: Emerging Concepts in B cell Directed Therapies. . . . . . . . . . . . . . . . . . . . 23 Disclosure: Neostasis, 5 ACR REF Within Our Reach: Finding a Cure for Rheumatoid Arthritis . . . . . . . . . . . . . 45 Disclosure: Neostasis, 5 Silverman, Stuart L, MD Controversies in Osteoporosis and Low Bone Mass: Who Do We Treat, For How Long, and at What Risks? . . . . . . . . . . . . . . . . . .103 Disclosure: Nothing to Disclose Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm. . . . . . . . . . . . . . . . . . . . . . . . . . . 33, 62 Disclosure: Nothing to Disclose 2010 Program Book 311 INVITED SPEAKER /MODERATOR INDEX
Page 1 and 2:
program B O O K Pre-Conference Cour
Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
Page 11 and 12:
the written consent of the ACR is p
Page 13 and 14:
Shuttle Bus Service See shuttle sig
Page 15 and 16:
ACR Resource Center Hours: Sunday,
Page 17 and 18:
ACR Hotels + Map Complimentary shut
Page 19 and 20:
to the premier meeting in rheumatol
Page 21 and 22:
ACR Clinical Research Conference c/
Page 23 and 24:
4:20 PM Germinal Center Reactions A
Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
Page 27 and 28:
Upon completion of this session, pa
Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
Page 31 and 32:
B301 Dermatological Manifestations
Page 33 and 34:
Session Overview: The innate immune
Page 35 and 36:
Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
Page 39 and 40:
and insufficiency • recall source
Page 41 and 42:
Session Overview: The advent of bio
Page 43 and 44:
2:45 pm 641. Major Improvements in
Page 45 and 46:
5 University of Twente and Medisch
Page 47 and 48:
ACR/ARHP Combined Abstract Session
Page 49 and 50:
REF 25th Anniversary Celebration 2:
Page 51 and 52:
5:45 PM 699. Defining Latent and/or
Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
Page 59 and 60:
• discuss the principles of early
Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
Page 65 and 66:
ACR Plenary Session II: Discovery 2
Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
Page 69 and 70:
Session Overview: As a clinical edu
Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
Page 77 and 78:
2:45 PM 1405. Development of a Visi
Page 79 and 80:
4:30 PM Anti-citrullinated Protein
Page 81 and 82:
of Experimental Orthopedics, Univer
Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
Page 91 and 92:
• compare the prevalence and epid
Page 93 and 94:
6:45 PM Macrophage Activation Syndr
Page 95 and 96:
Page 97 and 98:
Session Overview: This roundtable d
Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
Page 103 and 104:
• describe the role of IL-1 and I
Page 105 and 106:
Session Overview: For the clinician
Page 107 and 108:
• identify the aspects for day-to
Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
Page 111 and 112:
Session Overview: Ultrasound and ma
Page 113 and 114:
Session Overview: Fifty percent of
Page 115 and 116:
1:20 PM Academic Rheumatology Seth
Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
Page 123 and 124:
Session Overview: We are witnessing
Page 125 and 126:
Session Overview: Systemic sclerosi
Page 127 and 128:
Oaks, CA, 2 Amgen Inc., San Francis
Page 129 and 130:
5:00 PM 2176. A Role of Autoimmune
Page 131 and 132:
4:30 PM 2198. Association between V
Page 133 and 134:
ARHP Concurrent Sessions 4:30 - 6:0
Page 135 and 136:
THURSDAY, NOVEMBER 11, 2010 ACR/ARH
Page 137 and 138:
• apply these basic statistics to
Page 139 and 140:
9:15 AM The ACR/EULAR Definition of
Page 141 and 142:
Immunology, Oslo University Hospita
Page 143 and 144:
9:15 AM 2239. Factors Associated wi
Page 145 and 146:
Page 147 and 148:
Mikkel Østergaard 6 , Paul Emery 4
Page 149 and 150:
Ende 4 , 1 Department of Rheumatolo
Page 151 and 152:
ACR Poster Session A Cytokines, Med
Page 153 and 154:
ACR Poster Session A 51. Associatio
Page 155 and 156:
ACR Poster Session A 83. Respirator
Page 157 and 158:
ACR Poster Session A 121. Bone Dens
Page 159 and 160:
ACR Poster Session A 142. The Intra
Page 161 and 162:
ACR Poster Session A 171. Early Pro
Page 163 and 164:
ACR Poster Session A Pediatric Rheu
Page 165 and 166:
ACR Poster Session A 233. Prevalenc
Page 167 and 168:
ACR Poster Session A 266. Subtype S
Page 169 and 170:
ACR Poster Session A 297. Body Weig
Page 171 and 172:
ACR Poster Session A 325. Patient R
Page 173 and 174:
ACR Poster Session A 356. Influence
Page 175 and 176:
ACR Poster Session A 383. Efficacy
Page 177 and 178:
ACR Poster Session A 409. Rituximab
Page 179 and 180:
ACR Poster Session A 441. Recombina
Page 181 and 182:
ACR Poster Session A 465. Immunoglo
Page 183 and 184:
ACR Poster Session A 496. IRF8 Alle
Page 185 and 186:
ACR Poster Session A 521. DC-STAMP
Page 187 and 188:
ACR Poster Session A 546. Prevalenc
Page 189 and 190:
ACR Poster Session A 571. Epidemiol
Page 191 and 192:
ACR Poster Session A 599. Validatio
Page 193 and 194:
ACR/ARHP Poster Session B Halls B1
Page 195 and 196:
ACR Poster Session B 767. Economic
Page 197 and 198:
ACR/ARHP Poster Session B 792. The
Page 199 and 200:
ACR/ARHP Poster Session B Universit
Page 201 and 202:
ACR/ARHP Poster Session B 848. Cell
Page 203 and 204:
ACR/ARHP Poster Session B 886. Scre
Page 205 and 206:
ACR/ARHP Poster Session B 909. Regu
Page 207 and 208:
ACR/ARHP Poster Session B 935. The
Page 209 and 210:
ACR/ARHP Poster Session B 967. Frac
Page 211 and 212:
ACR Poster Session B 993. Early Exp
Page 213 and 214:
ACR/ARHP Poster Session B 1022. Com
Page 215 and 216:
ACR/ARHP Poster Session B 1055. Son
Page 217 and 218:
ACR Poster Session B 1084. Gene Exp
Page 219 and 220:
ACR/ARHP Poster Session B 1111. Inc
Page 221 and 222:
ACR Poster Session B hiroshima Memo
Page 223 and 224:
ACR/ARHP Poster Session B 1166. Pre
Page 225 and 226:
ACR/ARHP Poster Session B 1199. Typ
Page 227 and 228:
ACR/ARHP Poster Session B 1225. Phy
Page 229 and 230:
ACR/ARHP Poster Session B 1262. Lat
Page 231 and 232:
ACR/ARHP Poster Session B 1294. End
Page 233 and 234:
ACR/ARHP Poster Session B 1321. Cha
Page 235 and 236:
ACR/ARHP Poster Session C Halls B1
Page 237 and 238:
ACR/ARHP Poster Session C 1495. S10
Page 239 and 240:
ACR/ARHP Poster Session C 1524. Inc
Page 241 and 242:
ACR/ARHP Poster Session C 1555. Pro
Page 243 and 244:
ACR/ARHP Poster Session C 1583. Ass
Page 245 and 246:
ACR/ARHP Poster Session C 1596. Gen
Page 247 and 248:
ACR/ARHP Poster Session C 1622. Flu
Page 249 and 250:
ACR/ARHP Poster Session C Miscellan
Page 251 and 252:
ACR/ARHP Poster Session C L. Woodwa
Page 253 and 254:
ACR/ARHP Poster Session C 1692. Res
Page 255 and 256:
ACR/ARHP Poster Session C 1719. Los
Page 257 and 258:
ACR/ARHP Poster Session C 1749. Con
Page 259 and 260:
ACR/ARHP Poster Session C 1780. Tow
Page 261 and 262: ACR/ARHP Poster Session C 1804. Eff
Page 263 and 264: ACR/ARHP Poster Session C Immunolog
Page 265 and 266: ACR/ARHP Poster Session C 2 Departm
Page 267 and 268: ACR/ARHP Poster Session C CA, 29 Un
Page 269 and 270: ACR/ARHP Poster Session C 1900. IL-
Page 271 and 272: ACR/ARHP Poster Session C 1930. Cor
Page 273 and 274: ACR/ARHP Poster Session C 1958. The
Page 275 and 276: ACR/ARHP Poster Session C 1988. Cha
Page 277 and 278: ACR/ARHP Poster Session C 2015. CpG
Page 279 and 280: ACR/ARHP Poster Session C 2038. Pri
Page 281 and 282: ACR/ARHP Poster Session C 2070. Ass
Page 283 and 284: REF Industry Roundtable-supported S
Page 285 and 286: REF Industry Roundtable-supported S
Page 287 and 288: INDUSTRY-SUPPORTED POST-CONFERENCE
Page 289 and 290: 2010 ACR/ARHP Annual Meeting Leader
Page 291 and 292: 2010 ACR/ARHP Annual Meeting Leader
Page 293 and 294: FLOOR PLANS 2010 Program Book 291
Page 295 and 296: VISIT THE EXHIBIT HALL New and inno
Page 297 and 298: EXHIBITORS La Lettre Du Rhumatologu
Page 299 and 300: ACKNOWLEDGEMENTS The ACR, the ARHP
Page 301 and 302: ACR/ARHP/REF STAFF LISTING Administ
Page 303 and 304: A Ahmed, Rafi, PhD T cell Memory .
Page 305 and 306: Cooper, Max D, MD Introduction . .
Page 307 and 308: Gerlag, Danielle Marie, MD, PhD The
Page 309 and 310: Physical Examination Skills for Imp
Page 311: Meroni, Pierluigi, MD Autoantibodie
Page 315 and 316: Terkeltaub, Robert, MD Crystallizin
Page 317 and 318: A Aarden, L 1825 Aarrass, S 1519, 1
Page 319 and 320: Bakker, AAB 1095 Barendregt, B 753
Page 321 and 322: Boutin-Le Thi Huong, D 478 Bout-Tab
Page 323 and 324: Chatham, WW 457, 1146, 1454, 1457,
Page 325 and 326: Daudon, M 875 Daugas, E 2009 Davatc
Page 327 and 328: Ehst, B 758 Eicher, JL 688 Eisen, S
Page 329 and 330: Gabay, OH 1484 Gaber, T 630, 1418 G
Page 331 and 332: Guan, M 965 Guañabens, N 975 Gudbj
Page 333 and 334: Homme, CL 730 Honda, E 434 Hong, JY
Page 335 and 336: Kambayashi, T 1354 Kamdar, AA 1160
Page 337 and 338: Kuller, LH 71 Kumabe, M 1164 Kumaga
Page 339 and 340: Looney, C 941 Looney, MR 609 Looney
Page 341 and 342: McCarthy, GM 1109, 1306, 1426 McCau
Page 343 and 344: Myouzen, K 1577 Mysiw, WJ 2096 Mysl
Page 345 and 346: Pans, M 1834 Parra, ER 605, 887 Ped
Page 347 and 348: Radka, S 1174 Radner, H 296, 1745 R
Page 349 and 350: Sack, KE 1898 Sacli, SF 1312 Saddic
Page 351 and 352: 1463, 2071, 2140, 2141 Singh, K 212
Page 353 and 354: Takahata, M 1492 Takasaki, Y 1731 T
Page 355 and 356: 636 van Dongen, CJJ 90 Van Doornum,
Page 357 and 358: Witte, T 824, 1578, 1579, 2214 Witt
Page 359 and 360: A α-galactosylceramide 505 A2A kno
Page 361 and 362: Behcet’s syndrome 1284, 1288, 129
Page 363 and 364:
cost-utility 759, 1539 couples 1324
Page 365 and 366:
fibroblast like synoviocyte 27 fibr
Page 367 and 368:
impact 1063, 1325 inactive disease
Page 369 and 370:
methylation 826, 1253, 1489 methylt
Page 371 and 372:
233, 234, 240, 243, 252, 262, 268,
Page 373 and 374:
1599, 1600, 1603, 1605, 1606, 1609,
Page 375 and 376:
1226, 1227, 1229, 1230, 1231, 1233,
Page 377 and 378:
Abelson, Abby Goulder, MD Education
Page 379 and 380:
Massarotti, Elena M, MD Systemic Lu
Page 381 and 382:
ACR Annual Meeting fellowS-in-train
Page 383 and 384:
NOTES 2010 Program Book 381
Page 385 and 386:
Enbrel ® (etanercept) Brief Summar
Page 387 and 388:
Prescription Enbrel ® (etanercept)
show all

B O O K - American College of Rheumatology

Create successful ePaper yourself

Delete template?

Save as template?